Galectin Therapeutics Inc.
Company Snapshot: Galectin Therapeutics Inc.
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.
- Oct 27 2021 Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
- Oct 5 2021 UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
- Oct 5 2021 Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
- Sep 21 2021 Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein